Alvotech Files First-Ever Biosimilar Application for Eylea 8 mg in Europe
ALVO sits 84% above its 52-week low of $2.94 on light trading volume (0.2× avg).
Summary
Alvotech filed the first worldwide regulatory application for a biosimilar to Eylea 8 mg, a high-dose eye treatment that now accounts for over half of global Eylea sales.
Key Events · Product Development and Regulatory · ALVO
-
First-Ever Eylea 8 mg Biosimilar Filing
Alvotech and Advanz Pharma submitted AVT29 to the European Medicines Agency as a line extension to the existing Mynzepli marketing authorization — the first regulatory submission worldwide for a proposed biosimilar to Eylea 8 mg.
-
High-Dose Market Opportunity
The 8 mg formulation accounted for approximately 57% of combined global Eylea 2 mg and 8 mg sales by value in Q2 2026, up from ~30% in Q2 2025, indicating a large and growing addressable market.
-
Partnership Structure
Under the existing agreement, Alvotech handles development and commercial supply while Advanz Pharma manages registration and commercialization in Europe, with exclusive rights except semi-exclusive rights in Germany and France.
-
Regulatory Timeline
The application was submitted on October 14, 2026; approval timing is not specified, but the filing leverages the existing Mynzepli authorization, potentially streamlining review.
Analysis · ALVO · Life Sciences
A European regulatory application for AVT29, a proposed biosimilar to Eylea 8 mg (aflibercept 114.3 mg/mL), has been submitted by Alvotech and Advanz Pharma. This marks the first regulatory submission worldwide for a high-dose Eylea biosimilar, positioning Alvotech ahead of competitors in the next wave of aflibercept biosimilars. The 8 mg formulation already represents ~57% of global Eylea sales by value, so capturing this market could be a significant revenue driver. The submission builds on the August 2025 European approval of Mynzepli (2 mg), leveraging the same partnership structure where Advanz Pharma handles registration and commercialization in Europe.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 30.6% of the 1584 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALVO was trading at $5.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $2.94 to $9.05. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.